| Zacks Company Profile for Titan Pharmaceuticals, Inc. (TTNP : NSDQ) |
|
|
| |
| • Company Description |
| Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Number of Employees: 4 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $4.35 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 22,457 shares |
| Shares Outstanding: 0.91 (millions) |
| Market Capitalization: $3.98 (millions) |
| Beta: 1.27 |
| 52 Week High: $10.00 |
| 52 Week Low: $3.03 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-9.56% |
-13.29% |
| 12 Week |
18.85% |
4.15% |
| Year To Date |
33.44% |
26.03% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Chay Weei Jye - Chief Executive Officer
Brynner Chiam - Director
Avraham Ben-Tzvi, - Director
Firdauz Edmin Bin Mokhtar - Director
Francisco Osvaldo Flores Garcia - Director
|
|
Peer Information
Titan Pharmaceuticals, Inc. (CORR.)
Titan Pharmaceuticals, Inc. (RSPI)
Titan Pharmaceuticals, Inc. (CGXP)
Titan Pharmaceuticals, Inc. (BGEN)
Titan Pharmaceuticals, Inc. (GTBP)
Titan Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 888314705
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/21/25
|
|
Share - Related Items
Shares Outstanding: 0.91
Most Recent Split Date: 1.00 (0.05:1)
Beta: 1.27
Market Capitalization: $3.98 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/21/25 |
|
|
|
| |
